Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply
Article first published online: 12 AUG 2013
© 2013 John Wiley & Sons Ltd
Alimentary Pharmacology & Therapeutics
Volume 38, Issue 5, pages 554–555, September 2013
How to Cite
Talal, A. H., LaFleur, J., Hoop, R. S., Pandya, P., Martin, P., Jacobson, I. M., Han, J. and Korner, E. J. (2013), Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply. Alimentary Pharmacology & Therapeutics, 38: 554–555. doi: 10.1111/apt.12424
- Issue published online: 12 AUG 2013
- Article first published online: 12 AUG 2013
- Manuscript Accepted: 1 JUL 2013
- Manuscript Received: 30 JUN 2013
We thank Drs Aghemo and Lampertico for their commentary on our work.[1, 2] We agree that the investigation provides evidence to support the notion that medical contraindications to interferon (IFN) and ribavirin are not the major obstacles to low rates of hepatitis C virus (HCV) treatment initiation when using IFN-based therapies. However, we disagree with the hypothesis that ‘introduction of IFN-free regimens will only increase the number of anti-HCV treatment eligible patients by 10–15%’ for a few reasons.
First, our sample was derived from the general US population, which historically has had a much lower rate of HCV infection in comparison with that found among specific groups, such as veterans and persons who inject drugs. Indeed, HCV infection was only identified in 0.5% of patients in our data set, a percentage well below the US national average of 2%. Secondly, rates of medical comorbidities that are contraindications to IFN-based therapy, such as mental health issues, have been shown to be much higher in these population subgroups. Thirdly, a variety of other reasons at the patient, provider and institutional levels have historically played a larger role as reasons for aversion to initiate IFN-based therapy than have medical contraindications.
Some of these items, for example, patients’ fear of side effects attributable to IFN or former drug users’ concerns that medication administered by injection may foster relapse to injection drug use, factors that were not evaluated as part of our data set, will be significantly diminished if not entirely eliminated by removal of IFN from HCV therapeutic regimen. Others, such as expanded screening and HCV educational programmes, should improve with a multicomponent approach as outlined by Drs Aghemo and Lampertico.
The authors' declarations of personal and financial interests are unchanged from those in the original article.2
- 1Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C. Aliment Pharmacol Ther 2013; 38: 553–4., .
- 2Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Aliment Pharmacol Ther 2013; 37: 473–81., , , et al.
- 4Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772–9., , , et al.Direct Link: